BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Cantor Fitzgerald

Generated: March 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205782

« Back to Dashboard

NDA 205782 describes TRIAMCINOLONE ACETONIDE, which is a drug marketed by Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Fougera Pharms, G And W Labs, Glenmark Pharms Ltd, Lupin Atlantis, Morton Grove, Mylan Pharms Inc, Perrigo New York, Pharmaderm, Pharmafair, Taro, Teligent Pharma Inc, Topiderm, Vintage, Amneal Pharms Co, Parnell, Sandoz Inc, Watson Labs, Akorn, G And W Labs Inc, Wockhardt Bio Ag, Glenmark Pharms, Lyne, Perrigo Israel, Perrigo Uk Finco, Riconpharma Llc, and Cmp Pharma Inc, and is included in seventy-nine NDAs. It is available from sixty-four suppliers. Additional details are available on the TRIAMCINOLONE ACETONIDE profile page.

The generic ingredient in TRIAMCINOLONE ACETONIDE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Eighty-seven suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Pharmacology for NDA: 205782
Medical Subject Heading (MeSH) Categories for 205782
Suppliers and Packaging for NDA: 205782
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRIAMCINOLONE ACETONIDE triamcinolone acetonide SPRAY;TOPICAL 205782 ANDA Perrigo New York Inc 45802-045 N 45802-045-01
TRIAMCINOLONE ACETONIDE triamcinolone acetonide SPRAY;TOPICAL 205782 ANDA Perrigo New York Inc 45802-045 N 45802-045-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY;TOPICALStrength0.147MG/GM
Approval Date:Apr 13, 2015TE:ATRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.